Education Hub


Featured Resource

How to Leverage Real-World Evidence to Achieve Orphan Drug Designation

If you’re developing a drug targeting a rare disease, you may need support with the complexity of obtaining an ODD. An RWE study could be the most appropriate approach to estimate the epidemiology of a disease and indeed demonstrate if it is rare.

The FDA’s Project Orbis Can Speed up the Delivery of Your New Oncology Drug to Global Markets


Discover Key Healthcare and Life Sciences Insights

Our team of scientists, strategists, economists, clinicians, and biostatisticians stay on the cutting edge of the evolving landscape. We collect their insights here on our Education Hub and invite you to explore the latest thinking, key insights, and upcoming opportunities to connect with colleagues.



Content of Integrated Summaries of Efficacy and Safety (ISE/ISS)

This comprehensive guide to ISE/ISS content explains what the summaries must include for successful submission.



Forbes Best Management Consulting Firms

Alira Health Named One of the World's Best Management Consulting Firms

Alira Health is proud to announce it has been named by Forbes as one of the World's Best Management Consulting firms for 2023.



patient recruitment

Recruitment Challenges in Clinical Studies and How to Overcome Them

To gain insight on the challenges and typical paths to failure, as well as a wide array of solutions for successful patient recruitment, we spoke with two Alira Health experts, Annabel de Maria, Chief Patient Officer, and Chris Rao, Senior Vice President of Clinical Operations.

Webinars and Multimedia

Global Payer

Global Payer Forum: Navigating Value-Based Contracting

Join a series of educational webinars on Value-Based Contracting led by payers and academic experts.

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.